U.S. Markets closed

Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stock Research Monitor: APHB, APTO, and ABIO

LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 1.00%; the Dow Jones Industrial Average edged 0.75% higher; and the S&P 500 was up 0.97%. US markets made broad based gains with eight out of nine sectors finishing the day in green. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Aimmune Therapeutics Inc. (NASDAQ: AIMT), AmpliPhi Biosciences Corp. (NYSE AMER: APHB), Aptose Biosciences Inc. (NASDAQ: APTO), and ARCA biopharma Inc. (NASDAQ: ABIO). All you have to do is sign up today for this free limited time offer by clicking the link below.


Aimmune Therapeutics

Brisbane, California headquartered Aimmune Therapeutics Inc.'s stock finished Wednesday's session 6.68% lower at $28.92. A total volume of 1.16 million shares was traded, which was above its three months average volume of 1.06 million shares. The Company's shares have advanced 46.06% in the last twelve months. The stock is trading below its 50-day moving averages by 8.51%. Furthermore, shares of Aimmune Therapeutics, which develops and commercializes product candidates for the treatment of peanut and other food allergies, have a Relative Strength Index (RSI) of 37.64. Get the full research report on AIMT for free by clicking below at:


AmpliPhi Biosciences

Shares in San Diego, California headquartered AmpliPhi Biosciences Corp. ended the day flat at $1.09. The stock recorded a trading volume of 175,566 shares. The stock is trading below its 50-day moving average by 12.45%. Moreover, shares of AmpliPhi Biosciences, which focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology, have an RSI of 40.61. APHB's complimentary research coverage is a few simple steps away at:


Aptose Biosciences

Mississauga, Canada headquartered Aptose Biosciences Inc.'s stock ended yesterday's session 1.51% lower at $3.27 with a total trading volume of 126,491 shares. The Company's shares have advanced 17.63% over the previous three months and 163.71% in the last twelve months. The stock is trading above its 200-day moving average by 44.71%. Additionally, shares of Aptose Biosciences, which discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada, have an RSI of 48.35. Are you already registered with Wall St. Equities? Do so now for free, and get the report on APTO at:


ARCA biopharma

On Wednesday, shares in Westminster, Colorado headquartered ARCA biopharma Inc. recorded a trading volume of 111,142 shares. The stock finished the day 0.59% higher at $0.53. The Company's shares have advanced 5.80% in the last month. The stock is trading below its 50-day moving average by 7.93%. Furthermore, shares of ARCA biopharma, which focuses on developing genetically-targeted therapies for cardiovascular diseases, have an RSI of 47.61. Aspiring Member, please take a moment to register below for your free research report on ABIO at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities